Which ankle cartilage defects actually need OCA

For most ankle cartilage injuries, the first question a consultant needs to answer is whether the defect is within the size range that simpler techniques can reliably repair — or whether it has crossed the threshold where a fresh osteochondral allograft (OCA) becomes the right choice.

Size is the clearest guide. Chuckpaiwong et al. (2008) studied 105 ankle osteochondral lesions and found that marrow stimulation (microfracture) produced zero treatment failures for defects with an average diameter below 15 mm — but only a 3% success rate once that diameter was reached or exceeded. A complementary study by Choi et al. (2009), covering 168 lesions measured by MRI, placed the reliable upper limit for microfracture success at a lesion area of 150 mm² (roughly 1.5 cm²). Beyond these thresholds, and certainly once defect area exceeds 2–4 cm², OCA moves to the front of the treatment algorithm as the preferred restorative procedure.

Size, however, is not the only route to this decision. Two further situations point clearly toward OCA:

• Failed prior marrow stimulation. When microfracture has already been attempted and the cartilage has not recovered satisfactorily, OCA is the established rescue option.
• Subchondral bone loss or cystic change. Where damage extends into the bone beneath the cartilage surface, only a full osteochondral graft can restore both layers in a single procedure — bone grafting or marrow stimulation alone cannot address the combined defect.

OCA is therefore not the first treatment tried; it is the procedure designed for cases where less invasive options are insufficient from the outset, or have already been exhausted.

Why microfracture stops working above that threshold

The problem is not simply that microfracture struggles with bigger defects — it is that the tissue microfracture produces was never designed for long-term load in the first place.

When marrow stimulation is performed, the bleeding channels drilled into the bone attract stem cells that form a clot, which eventually matures into fibrocartilage. Fibrocartilage is the body's scar-tissue response to joint injury: tougher and less organised than the original hyaline cartilage that lines a healthy ankle. Hyaline cartilage is the joint's native surface — smooth, precisely structured, and capable of distributing load evenly over decades. Fibrocartilage cannot reliably replicate that function, and evidence suggests it begins to break down mechanically at around 12–18 months, a deterioration pattern observed consistently in medium-term follow-up.

The structural consequences compound over time. In one reported series, subchondral bone compaction and osseous overgrowth were present in 93% of microfracture failures. This matters beyond the immediate outcome: those bony changes alter the architecture beneath the cartilage surface, making subsequent repair procedures more technically demanding.

Spread across a large defect, these limitations accelerate. Fibrocartilage under greater total load breaks down faster and less predictably than fibrocartilage covering a small, well-contained area.

OCA addresses the problem at its root. Fresh donor tissue arrives with living chondrocytes already embedded in a structured cartilage matrix, supported by a bone plug that integrates with the host skeleton. The result is hyaline-like repair tissue — compositionally and biomechanically closer to the ankle's original surface — rather than a scar-tissue substitute that has a defined lifespan.

Where OATS fits — and why it hands off to OCA

Before OCA enters the picture, there is an intermediate option that suits a meaningful number of talar lesions: osteochondral autograft transfer, commonly called OATS or mosaicplasty. In a systematic review of 243 talar OLT patients, Zengerink et al. (2009) reported an 87% success rate — a strong result that reflects the technique's genuine value for moderate-sized defects, broadly up to around 1.5–2 cm² in area.

The key feature of OATS is that the cartilage plugs come from the patient's own knee, taken from a low-load zone where removal causes minimal functional loss. Those plugs arrive with living cartilage already intact, avoiding the fibrocartilage limitations described above. Donor-site morbidity — some discomfort or stiffness at the harvest site — remains a real consideration, however modest in most cases.

Two factors set the upper limit. First, there is only so much autograft that can safely be taken; the defect must fit within what a responsible harvest allows. Second, the talar dome is a curved surface, and as defect size grows, matching plug geometry to that curvature becomes progressively harder to achieve reliably.

Once defect area moves beyond what autograft can cover well, the clinical rationale for OCA becomes straightforward. Fresh allograft is sized directly to the defect — no donor-site constraint, no geometry compromise. That shift in indication is driven by defect area and the state of the underlying bone, not by any preference for one technique over another.

What OCA involves — the procedure and surgical access

Planning the procedure begins well before the operating theatre. CT imaging maps the bony depth and morphology of the defect in multiple planes, while MRI adds detail on cartilage involvement and any subchondral bone oedema beneath it. A supplementary CT taken with the foot in maximum plantar flexion helps determine whether the lesion is reachable arthroscopically, or whether open access will be required — an important staging decision that shapes the whole operative plan.

The graft is sourced from a deceased donor and processed as fresh tissue, specifically to preserve the living chondrocytes within it. The distinction between fresh and frozen matters here: freezing, used in some tissue-bank protocols to extend shelf life, kills those cells. A fresh allograft retains them, which is the basis of its biological advantage over processed alternatives.

Accessing a large talar OLT is one of the more technically demanding aspects of the operation. The talar dome sits deep within the ankle joint, and most substantial medial lesions can only be visualised and instrumented adequately through a chevron-type medial malleolar osteotomy — a controlled cut through the inner ankle bone that opens the joint sufficiently to implant the graft, then is secured back with screws at the end of the case. Lateral lesions require a tibial trapezoidal osteotomy for the same exposure.

The osteotomy introduces a second healing process alongside the graft itself. Patients should expect that recovery reflects both, and discussing this with their consultant before surgery is an important part of the consent process.

Realistic outcomes and what recovery looks like

The survivorship figures most often cited in OCA counselling come primarily from knee series. In one large cohort, graft survivorship was 82.6% at five years and 69.6% at ten years; a separate analysis found 44 of 65 grafts (68%) in situ and functioning at a mean of 12.9 years, corresponding to 95% survivorship by the study's endpoint criteria. At a mean six-year follow-up, 75.2% of patients had returned to sport or recreational activity, and 71% rated their outcome as 'very good' or 'excellent'.

These numbers are genuinely encouraging — but they apply to the knee. Ankle cartilage has a lower water content and a higher glycosaminoglycan concentration than its knee counterpart, producing a distinctly different biomechanical environment and a different biological response to repair. Whether the knee survivorship curves translate meaningfully to the talus is not established, and ankle-specific OCA series — particularly those with follow-up beyond ten years — remain limited. Comparative randomised data against ACI or MACI for large talar defects are also scarce. This is the honest state of current evidence: a strong biological rationale and consistently good structural results, but the long-term talar-specific data needed to draw firm conclusions are still accumulating. Good practice in pre-operative discussion reflects that uncertainty plainly, so patients understand what the evidence supports and where its limits currently lie.

What the evidence does support clearly is the rehabilitation trajectory. Return to low-impact activity is typically achievable at four to six months; higher-impact sport comes at nine to twelve months. That longer timeline reflects the time required for graft bone to incorporate into the talar host bed — a biological process that cannot be compressed without risk of mechanical failure.

Getting assessed for OCA at MSK Doctors

Candidacy for OCA rests on three clinical questions: how large and how deep is the defect, how much subchondral bone has been lost or cystic change is present, and whether an earlier procedure has already been attempted. Patients who are most likely to benefit are those with defects exceeding roughly 15 mm in average diameter or 150 mm² in area, significant bone involvement beneath the cartilage surface, or a failed prior marrow-stimulation or autograft procedure. Those with smaller, contained lesions and intact subchondral bone are typically better served by OATS or a scaffold-based approach first.

Answering those questions accurately requires CT — to map bony morphology and defect depth across multiple planes — alongside MRI for cartilage quality and subchondral oedema. At MSK Doctors, that assessment is consultant-led from the outset, without the need for a GP referral or NHS waiting times. Imaging is available at the Sleaford and Grantham sites; patients based in London can access the same specialist pathway through the London Cartilage Clinic.

Appointments can be arranged directly at mskdoctors.com.